Abstract: Objective To evaluate the clinical treatment value of CT-guided percutaneous lung centesis administration in treatment of cavernous multi-drug resistant pulmonary tuberculosis. Methods66 patients with cavernous multi-drug resistant pulmonary tuberculosis were randomized 1∶1 to experimental group and control group. 33 patients in experimental group received CT-guided percutaneous lung centesis administration combined with antituberculosis treatment, and 33 patients in control group received anti-tuberculosis treatment alone. The short-term and long-term clinical treatment outcomes were observed. ResultsAt the end of the treatment, the sputum negative conversion rate was 70%, foci absorption rate was 73.3%，and cavity closure rate was 50% in the experimental group, all of which were higher than those of the controls (41.9%，41.9%and 19.4%)(P<0.05). The patients with the sputum negative conversion at the end of the treatment in two groups were followed up for 1～2 years, and one case was recurrent in each group(4.8% and 6.3%). There was no statistically significant difference on recurrent rates in two groups(P>0.05). There were not severe adverse reactions observed in the experimental group. ConclusionThe short-term and long-term clinical treatment outcome of CT-guided percutaneous lung centesis administration in treatment of cavernous multi-drug resistant pulmonary tuberculosis were both better than those of the routine antituberculosis treatment alone. The combined treatment approach was safe and has few side effects.

Key words: pulmonary tuberculosis, multidrug-resistant, centesis